Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.

Last updated on 3-1-2024 by Marie Malingreau

Public Access


Peer reviewed scientific article


Article written during project(s) : 


Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV® Screening (SCR) is a partial genotyping multiplex real-time PCR assay targeting E6/E7 genes of 13 high-risk (hr) HPVs. OncoPredict HPV® SCR (index assay) identifies HPV-16 and HPV-18 separately, 11 other hrHPV in aggregate and includes quality controls for sample adequacy, DNA extraction efficiency and PCR inhibition. 1300 VALGENT-2 study samples (from women aged 20-60 attending the Scottish cervical cancer screening program) were tested wi…

Associated health topics:

QR code

QR code for this page URL